1. Home
  2. Topics
  3. EP4 Antagonist RQ-00000007 Clinical Study Initiated in the People’s Republic of China

Topics

EP4 Antagonist RQ-00000007 Clinical Study Initiated in the People’s Republic of China

 

RMX Biopharma Co., Ltd (Headquarter in Hongzhou, China, CEO: RuiPing Dong) (RMX), initiated a clinical study with grapiprant in the People’s Republic of China (China) on September 20, 2018. RMX licensed our licensee AskAt Inc. for pain indications in China on January 1, 2016.

 

This is the first clinical trial in China. Grapiprant has previously demonstrated efficacy, safety, and tolerability in Phase 2 clinical trials in the United States for osteoarthritis-associated pain.

 

Under the license agreement between RaQualia and AskAt, RaQualia is eligible to receive development milestones and royalties on sales of the product.

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics